View Filing Data

Print Document View Excel Document

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Jun. 30, 2012	Jul. 31, 2012
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2012
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2012
Entity Registrant Name	Stereotaxis, Inc.
Entity Central Index Key	0001289340
Current Fiscal Year End Date	--12-31
Trading Symbol	stxs
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		7,803,921

Balance Sheets - USD ($)	Jun. 30, 2012	Dec. 31, 2011
Assets
Cash and cash equivalents	$ 12,119,450	$ 13,954,919
Accounts receivable, net of allowance of $713,142 and $667,529 in 2012 and 2011, respectively	8,235,138	11,104,038
Current portion of long-term receivables	60,692	59,679
Inventories	7,378,595	6,036,051
Prepaid expenses and other current assets	3,858,824	3,081,484
Total current assets	31,652,699	34,236,171
Property and equipment, net	2,763,723	3,323,856
Intangible assets, net	2,129,236	2,279,153
Long-term receivables	31,581	51,892
Other assets	38,616	40,760
Total assets	36,615,855	39,931,832
Liabilities and stockholders' deficit
Short-term debt and current maturities of long-term debt	13,891,182	21,173,321
Accounts payable	4,635,569	5,610,181
Accrued liabilities	5,947,702	5,703,166
Deferred revenue	7,535,373	8,220,306
Warrants and debt conversion features	2,079,104	125,415
Total current liabilities	34,088,930	40,832,389
Long-term debt, less current maturities	15,237,558	17,290,531
Long-term deferred revenue	766,860	634,713
Other liabilities	787	3,094
Stockholders' deficit:
Common stock, par value $0.001; 100,000,000 shares authorized at 2012 and 2011, 7,812,206 and 5,431,157 shares issued at 2012 and 2011, respectively	7,812	5,543
Additional paid in capital	365,133,838	356,779,007
Treasury stock, 4,015 shares at 2012 and 2011	(205,999)	(205,999)
Accumulated deficit	(378,413,931)	(375,407,446)
Total stockholders' deficit	(13,478,280)	(18,828,895)
Total liabilities and stockholders' deficit	$ 36,615,855	$ 39,931,832

Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2012	Dec. 31, 2011
Balance Sheets [Abstract]
Accounts receivable, allowance	$ 713,142	$ 667,529
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	7,812,206	5,543,157
Treasury stock, shares	4,015	4,015

Statements Of Operations - USD ($)	3 Months Ended		6 Months Ended
Statements Of Operations - USD ($)	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
Revenue:
Systems	$ 3,863,107	$ 5,024,543	$ 9,042,612	$ 9,312,719
Disposables, service and accessories	6,649,791	6,577,596	13,753,514	12,514,124
Total revenue	10,512,898	11,602,139	22,796,126	21,826,843
Cost of revenue:
Systems	2,175,971	2,520,431	4,518,381	4,704,909
Disposables, service and accessories	1,084,107	995,915	2,503,528	1,816,416
Total cost of revenue	3,260,078	3,516,346	7,021,909	6,521,325
Gross margin	7,252,820	8,085,793	15,774,217	15,305,518
Operating expenses:
Research and development	2,196,073	3,311,177	5,021,280	6,705,436
Sales and marketing	6,223,330	9,712,519	12,222,069	18,050,855
General and administrative	3,469,346	4,606,555	7,342,219	8,856,824
Total operating expenses	11,888,749	17,630,251	24,585,568	33,613,115
Operating loss	(4,635,929)	(9,544,458)	(8,811,351)	(18,307,597)
Other income (expense)	9,269,424	620,409	9,081,354	640,755
Interest income	2,008	2,133	3,371	5,320
Interest expense	(1,829,076)	(772,769)	(3,279,859)	(1,583,096)
Net loss	$ 2,806,427	$ (9,694,685)	$ (3,006,485)	$ (19,244,618)
Net earnings (loss) per common share:
Basic	$ 0.42	$ (1.77)	$ (0.49)	$ (3.51)
Diluted	$ 0.32	$ (1.77)	$ (0.49)	$ (3.51)
Weighted average shares used in computing net earnings (loss) per common share:
Basic	6,741,578	5,478,087	6,120,447	5,475,044
Diluted	9,263,149	5,478,087	6,120,447	5,475,044

Statements Of Cash Flows - USD ($)	6 Months Ended
Statements Of Cash Flows - USD ($)	Jun. 30, 2012	Jun. 30, 2011
Cash flows from operating activities
Net loss	$ (3,006,485)	$ (19,244,618)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	669,040	731,101
Amortization	149,917	149,916
Amortization of deferred financing costs and debt discount	1,366,471	660,302
Share-based compensation	1,794,729	1,582,866
Loss on asset disposal	4,122
Non-cash royalty (income), net		(1,597,685)
Adjustment of warrants and debt conversion features	(9,081,354)	(640,755)
Changes in operating assets and liabilities:
Accounts receivable	2,868,900	3,737,168
Other receivables	19,298	(3,935)
Inventories	(1,342,544)	(473,568)
Prepaid expenses and other current assets	(398,952)	311,230
Other assets	2,144	(6,071)
Accounts payable	(974,612)	(866,138)
Accrued liabilities	71,203	884,923
Deferred revenue	(552,786)	18,939
Other liabilities	(2,307)	(4,894)
Net cash used in operating activities	(8,413,216)	(14,761,219)
Cash flows from investing activities
Purchase of equipment	(113,030)	(615,523)
Net cash used in investing activities	(113,030)	(615,523)
Cash flows from financing activities
Payments of term note	(2,000,000)
Proceeds from revolving line of credit	33,073,407	32,909,375
Payments of revolving line of credit	(40,363,204)	(28,100,000)
Proceeds from subordinated convertible debt, net of issuance costs	7,738,351
Payments of Cowen Debt	(925,533)
Payments of Biosense Debt		(1,572,587)
Proceeds from issuance of stock and warrants, net of issuance costs	9,167,756	151,600
Net cash provided by financing activities	6,690,777	3,388,388
Net decrease in cash and cash equivalents	(1,835,469)	(11,988,354)
Cash and cash equivalents at beginning of period	13,954,919	35,248,819
Cash and cash equivalents at end of period	$ 12,119,450	$ 23,260,465

Description Of Business	6 Months Ended
Description Of Business	Jun. 30, 2012
Description Of Business [Abstract]
Description Of Business	*1. Description of Business* Stereotaxis designs, manufactures and markets the Epoch Solution, which is an advanced remote robotic navigation system for use in a hospital’s interventional surgical suite, or “interventional lab”, that we believe revolutionizes the treatment of arrhythmias and coronary artery disease by enabling enhanced safety, efficiency and efficacy for catheter-based, or interventional, procedures. The Epoch Solution is comprised of the Niobe ES Robotic Magnetic Navigation System (“Niobe ES system”), Odyssey Information Management Solution (“Odyssey Solution”), and the Vdrive Robotic Navigation System. The Niobe system is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, efficient procedures and reduced x-ray exposure. In addition to the Niobe system and its components, Stereotaxis also has developed the Odyssey Solution, which consolidates all lab information enabling doctors to focus on the patient for optimal procedure efficiency. The system also features a remote viewing and recording capability called Odyssey Cinema, which is an innovative solution delivering synchronized content for optimized workflow, advanced care and improved productivity. This tool includes an archiving capability that allows clinicians to store and replay entire procedures or segments of procedures. This information can be accessed from locations throughout the hospital local area network and over the global Odyssey Network providing physicians with a tool for clinical collaboration, remote consultation and training. Our Vdrive Robotic Navigation System provides navigation and stability for diagnostic and therapeutic devices designed to improve interventional procedures. The Vdrive Robotic Navigation System complements the Niobe ES system control of therapeutic catheters for fully remote procedures and enables single-operator workflow and is sold as two options, the Vdrive System and the Vdrive Duo System. In addition to the Vdrive System and the Vdrive Duo System, we also manufacture and market various disposable components which can be manipulated by these systems. We promote the full Epoch Solution in a typical hospital implementation, subject to regulatory approvals or clearances. The full Epoch Solution implementation requires a hospital to agree to an upfront capital payment and recurring payments. The upfront capital payment typically includes equipment and installation charges. The recurring payments typically include disposable costs for each procedure, equipment service costs beyond warranty period, and software licenses and Odyssey Network fees. In hospitals where the full Epoch Solution has not been implemented, equipment upgrade or expansion can be implemented upon purchasing of the necessary upgrade or expansion. The core components of Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere; the V-Loop™ circular catheter manipulator is currently under regulatory review by the U.S. Food and Drug Administration. Since our inception, we have generated significant losses. As of June 30, 2012, we had incurred cumulative net losses of approximately $378 million. The Company expects such losses to continue through at least the year ended December 31, 2012. In May 2011, the Company introduced the Niobe ES, which is the latest generation of the Niobe Robotic Magnetic Navigation System and will replace the Niobe II system going forward. Due to the fact that the Niobe ES system and upgrades from Niobe II to Niobe ES systems were not available to customers until December 2011, the product change created a rapid shift away from sales of the current Niobe II system, resulting in lower System Revenue in 2011. As of June 30, 2012, the Company had performed 47 installations to upgrade Niobe II systems to Niobe ES systems and has received positive feedback from the physicians at these sites. On May 8, 2012, the Company announced that it expects to reduce operating expenses by 15 -20% from first quarter levels by the fourth quarter of 2012. In May 2012, the Company entered into financing agreements and received gross proceeds of approximately $18.5 million. Upon closing the financing transactions, the Company amended its agreement with its primary lender. See Notes 9 and 10 for additional details.

Summary Of Significant Accounting Policies

6 Months Ended

Jun. 30, 2012

Summary Of Significant Accounting Policies [Abstract]

Summary Of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited financial statements of Stereotaxis, Inc. have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all the disclosures required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of management, they include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods presented. Operating results for the six month period ended June 30, 2012 are not necessarily indicative of the results that may be expected for the year ended December 31, 2012 or for future operating periods.

These interim financial statements and the related notes should be read in conjunction with the annual financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011 as filed with the Securities and Exchange Commission (SEC) on March 15, 2012.

As described in Note 10, on July 10, 2012, the Company effected a one-for-ten reverse stock split of the Company’s common stock. All information set forth in the financial statements and related notes gives effect to such reverse stock split.

Revenue and Costs of Revenue

For arrangements with multiple deliverables, the Company allocates the total revenue to each deliverable based on the provisions of general accounting principles for revenue recognition and multiple-deliverable revenue arrangements and recognizes revenue for each separate element as the criteria for revenue recognition are met. Each element is assigned an estimated selling price using vendor-specific objective evidence, third party evidence, or management’s estimate.

Under our revenue recognition policy, a portion of revenue for the Niobe, Odyssey Vision, Odyssey Cinema, and Vdrive systems is recognized upon delivery, provided that title has passed, there are no uncertainties regarding acceptance, persuasive evidence of an arrangement exists, the sales price is fixed and determinable, and collection of the related receivable is reasonably assured. Revenue for Niobe, Odyssey Vision Standard HD, Odyssey Vision Quad, Odyssey Enterprise Cinema, and Vdrive systems is recognized upon delivery due to the fact that third parties became qualified to perform installations. Revenue is recognized for other types of Odyssey systems upon completion of installation, since there are no qualified third party installers. When installation is the responsibility of the customer, revenue from system sales is recognized upon shipment since these arrangements do not include an installation element or right of return privileges. The Company does not recognize revenue in situations in which inventory remains at a Stereotaxis warehouse or in situations in which title and risk of loss have not transferred to the customer. However, the Company may deliver systems to a non-hospital site at the customer’s request as outlined in the terms and conditions of the sales agreement, in which case the Company evaluates whether the substance of the transaction meets the delivery and performance requirements for revenue recognition under “bill and hold” guidance. Amounts collected prior to satisfying the above revenue recognition criteria are reflected as deferred revenue.

Revenue from services and license fees, whether sold individually or as a separate unit of accounting in a multiple-deliverable arrangement, is deferred and amortized over the service or license fee period, which is typically one year. Revenue from services is derived primarily from the sale of annual product maintenance plans. We recognize revenue from disposable device sales or accessories upon shipment and establish an appropriate reserve for returns. The return reserve, which is applicable only to disposable devices, is estimated based on historical experience which is periodically reviewed and updated as necessary. In the past, changes in estimate have had only a de minimus effect on revenue recognized in the period. We believe that the estimate is not likely to change significantly in the future.

Costs of systems revenue include direct product costs, installation labor and other costs, estimated warranty costs, and initial training and product maintenance costs. These costs are recorded at the time of sale. Costs of disposable revenue include direct product costs and estimated warranty costs and are recorded at the time of sale. Cost of revenue from services and license fees are recorded when incurred.

Net Earnings (Loss) per Common Share

Basic and diluted net earnings (loss) per common share is computed by dividing the net earnings (loss) for the period by the weighted average number of common shares outstanding during the period. On July 10, 2012, the Company effected a one-for-ten reverse stock split of the Company’s common stock. The net earnings (loss) per common share, shares outstanding, and weighted average shares outstanding reported in the financial statements and notes to the financial statements for the period ending June 30, 2012 are presented on a post-split basis. See Note 10 for additional discussion of the reverse stock split.

The following table sets forth the computation of basic and diluted EPS:

	Three months ended June 30,		Six months ended June 30,
	2012	2011	2012	2011
Numerator:
Numerator for basic EPS	$ 2,806,427	$ (9,694,685)	$ (3,006,485)	$ (19,244,618)

Effect of dilutive securities:
Convertible debentures	203,830	-	-	-

Numerator for diluted EPS	$ 3,010,257	$ (9,694,685)	$ (3,006,485)	$ (19,244,618)

Denominator:
Denominator for basic EPS - weighted average shares	6,741,578	5,478,087	6,120,447	5,475,044

Effect of dilutive securities:
Convertible debentures	2,521,571	-	-	-

Denominator for diluted EPS	9,263,149	5,478,087	6,120,447	5,475,044

Basic EPS	$ 0.42	$ (1.77)	$ (0.49)	$ (3.51)
Diluted EPS	$ 0.32	$ (1.77)	$ (0.49)	$ (3.51)

In the second quarter of 2012, the Company entered into a securities purchase agreement with certain institutional investors whereby the Company agreed to sell an aggregate of approximately $8.5 million in aggregate principal amount of unsecured, subordinated, convertible debentures, which became convertible into shares of the Company’s common stock at a conversion price of $3.361 per share (or approximately 2.5 million shares in the aggregate), on July 10, 2012, the date that the Company received shareholder approval for the transaction. Interest expense of $203,830 related to the subordinated convertible debentures was recorded for the period ended June 30, 2012. The interest expense includes interest paid as well as amortization of the debt discount. Refer to Note 9 for additional discussion of this transaction.

The following potential common shares were excluded from diluted EPS for the three months ended June 30, 2012 as they were antidilutive: 423,669 stock options and stock appreciation rights, 112,775 restricted share awards, 82,106 restricted stock units, and 6,099,476 warrants.

In addition, the Company did not include any portion of unearned restricted shares, outstanding options, stock appreciation rights or warrants in the calculation of diluted loss per common share because all such securities are anti-dilutive for the three and six months ended June 30, 2011 and the six months ended June 30, 2012. The application of the two-class method of computing earnings per share under general accounting principles for participating securities is not applicable during these periods because the Company’s unearned restricted shares do not contractually participate in its losses.

As of June 30, 2012, the Company had 423,669 shares of common stock issuable upon the exercise of outstanding options and stock appreciation rights at a weighted average exercise price of $44.95 per share and 6,099,476 shares of common stock issuable upon the exercise of outstanding warrants at a weighted average exercise price of $9.98 per share. The Company had a weighted average of 111,226 and 98,098 unearned restricted shares outstanding for the three and six months ended June 30, 2012.

Fair Value Measurements

The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash equivalents and warrants. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). See Note 11 for additional details.

The following methods and assumptions were used by the Company in estimating its fair value disclosures for other financial instruments as of June 30, 2012 and December 31, 2011.

Cash and cash equivalents, accounts receivable, accounts payable and accrued expenses have carrying values which approximate fair value due to the short maturity or the financial nature of these instruments.

Long and short-term debt fair value estimates are based on estimated borrowing rates to discount the cash flows to their present value. See Note 9 for disclosure of the fair value of debt.

Share-Based Compensation

The Company accounts for its grants of stock options, stock appreciation rights, restricted shares, and restricted stock units and for its employee stock purchase plan in accordance with the provisions of general accounting principles for share-based payments. These accounting principles require the determination of the fair value of the share-based compensation at the grant date and the recognition of the related expense over the period in which the share-based compensation vests.

The Company utilizes the Black-Scholes valuation model to determine the fair value of stock options and stock appreciation rights at the date of grant. The resulting compensation expense is recognized over the requisite service period, which is generally four years. Compensation expense is recognized only for those awards expected to vest, with forfeitures estimated based on the Company’s historical experience and future expectations. Restricted shares granted to employees are valued at the fair market value at the date of grant. The Company amortizes the amount to expense over the service period on a straight-line basis. If the shares are subject to performance objectives, the resulting compensation expense is amortized over the anticipated vesting period and is subject to adjustment based on the actual achievement of objectives.

Reclassifications

Common stock and additional paid-in capital in the prior year’s financial statements have been reclassified to reflect the one-for-ten reverse stock split effected on July 10, 2012. Refer to Note 10 for additional discussion of the reverse stock split.

Recently Issued Accounting Pronouncements

In December 2011, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2011-11, “Disclosures about Offsetting Assets and Liabilities.” The Update enhances the disclosure of offsetting assets and liabilities by requiring companies to disclose both the gross and net information about instruments and transactions eligible for offset as well as those subject to an agreement similar to master netting arrangements. This guidance is effective for the Company’s interim and annual periods beginning January 1, 2013. The Company is currently evaluating the impact of adoption on the financial statements.

In June 2011, the FASB issued new accounting guidance related to the presentation of comprehensive income that increases comparability between U.S. GAAP and International Financial Reporting Standards (“IFRS”). This guidance eliminates the current option to report other comprehensive income (OCI) and its components in the statement of changes in stockholders’ equity. This guidance was effective for the Company’s interim and annual periods beginning January 1, 2012. As the Company has no items of other comprehensive income, the Company is not required to report comprehensive income or other comprehensive income.

In May 2011, the FASB issued Accounting Standards Update No. 2011-04, “Fair Value Measurement: Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRS.” The Update amends the guidance on fair value measurements to develop common requirements for measuring fair value and for disclosing information about fair value measurements in accordance with U.S. GAAP and IFRS. The Update does not require additional fair value measurements and is not intended to establish valuation standards or affect valuation practices outside of financial reporting. This guidance was effective during interim and annual periods beginning after December 15, 2011. The adoption of this ASU did not have a material effect on our financial position or results of operations.

Inventory

6 Months Ended

Jun. 30, 2012

Inventory [Abstract]

Inventory

3. Inventory

Inventory consists of the following:


	June 30,	December 31,
	2012	2011

Raw materials	$3,532,122	$2,264,603
Work in process	354,344	131,980
Finished goods	3,723,835	3,790,625
Reserve for obsolescence	(231,706)	(151,157)
Total inventory	$7,378,595	$6,036,051

Prepaid Expenses And Other Current Assets

6 Months Ended

Jun. 30, 2012

Prepaid Expenses And Other Current Assets [Abstract]

Prepaid Expenses And Other Current Assets

4. Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following:


	June 30,	December 31,
	2012	2011

Prepaid expenses	$390,292	$460,297
Deferred cost of revenue	389,860	289,312
Derivative asset	3,951	-
Other assets	3,074,721	2,331,875
Total prepaid expenses and other current assets	$3,858,824	$3,081,484

Deferred cost of revenue represents the cost of systems for which title has transferred from the Company but for which revenue has not been recognized.

The derivative asset represents the fair value of a debt conversion feature that is part of the subordinated convertible debentures agreement. Refer to Notes 9 and 11 for discussion of the debentures and fair value measurement, respectively.

Property And Equipment

6 Months Ended

Jun. 30, 2012

Property And Equipment [Abstract]

Property And Equipment

5. Property and Equipment

Property and equipment consist of the following:


	June 30,	December 31,
	2012	2011

Equipment	$8,946,967	$8,977,623
Equipment held for lease	547,416	547,416
Leasehold improvements	2,473,880	2,473,880
	11,968,263	11,998,919
Less: Accumulated depreciation	(9,204,540)	(8,675,063)
Net property and equipment	$2,763,723	$3,323,856

- Definition

The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.

+ References + Details

Intangible Assets	6 Months Ended
Intangible Assets	Jun. 30, 2012
Intangible Assets [Abstract]
Intangible Assets	*6. Intangible Assets* On June 4, 2010, the Company entered into an agreement to issue 450,000 shares of its common stock to a consultant (the “Purchaser”) in exchange for intellectual property rights related to the Company’s products. The Company issued 20 0,000 shares upon execution of the agreement and will issue an aggregate of 250,000 shares in annual installments on the first three anniversaries of the agreement. The unissued shares meet the criteria for equity classification under Accounting Standards Codification (ASC) 480 Distinguishing Liabilities from Equity and therefore are recorded in additional paid-in capital. There was no cash consideration paid for the securities. The securities were issued in consideration of the assignment to the Company of the Purchaser’s rights in certain intellectual property, including patent applications, in all inventions and discoveries in the Company’s business field (as defined in the agreement) that had been developed under various other agreements, which were terminated. The securities were sold by the Company in a private placement exempt from registration under Section 4(2) of the Securities Act of 1933 and Regulation D promulgated thereunder. There were no underwriters or placement agents involved in the transaction. As of June 30, 2012, the Company had total intangible assets, including those described above, of $3.7 million. Accumulated amortization at June 30, 2012 was $1.6 million.

Accrued Liabilities

6 Months Ended

Jun. 30, 2012

Accrued Liabilities [Abstract]

Accrued Liabilities

7. Accrued Liabilities

Accrued liabilities consist of the following:


	June 30,	December 31,
	2012	2011

Accrued salaries, bonus, and benefits	$2,966,208	$3,229,382
Accrued research and development	19,547	27,044
Accrued legal and other professional fees	58,762	25,000
Other	2,903,185	2,421,740
Total accrued liabilities	$5,947,702	$5,703,166

Deferred Revenue

6 Months Ended

Jun. 30, 2012

Deferred Revenue [Abstract]

Deferred Revenue

8. Deferred Revenue

Deferred revenue consists of the following:


	June 30,	December 31,
	2012	2011

Product shipped, revenue deferred	$1,595,106	$2,001,160
Customer deposits	447,700	1,156,900
Deferred service and license fees	6,259,427	5,696,959
	8,302,233	8,855,019
Less: Long-term deferred revenue	(766,860)	(634,713)
Total current deferred revenue	$7,535,373	$8,220,306

Long-Term Debt And Credit Facilities

6 Months Ended

Jun. 30, 2012

Long-Term Debt And Credit Facilities [Abstract]

Long-Term Debt And Credit Facilities

9. Long-Term Debt and Credit Facilities

Debt outstanding consists of the following:

	June 30, 2012		December 31, 2011
	Carrying	Estimated	Carrying	Estimated
	Amount	Fair Value	Amount	Fair Value

Revolving line of credit, due March 2013	$ 8,000,000	$ 8,119,966	$ 15,290,510	$ 15,371,063
Term note, due December 2013	6,000,000	6,000,000	8,000,000	8,000,000
Cowen debt	14,075,189	14,075,189	15,173,342	15,173,342
Subordinated convertible debentures	1,053,551	1,053,551	-	-
Total debt	29,128,740	29,248,706	38,463,852	38,544,405
Less current maturities	(13,891,182)	(14,011,148)	(21,173,321)	(21,253,874)
Total long term debt	$ 15,237,558	$ 15,237,558	$ 17,290,531	$ 17,290,531

Revolving line of credit

The revolving line of credit and the Company’s term notes (collectively, the “Credit Agreements”) are secured by substantially all of the Company’s assets. The Company is also required under the Credit Agreements to maintain its primary operating account and the majority of its cash and investment balances in accounts with the primary lender.

In December 2010, the Company amended its agreement with its primary lender to extend the maturity of the current working capital line of credit from March 31, 2011 to March 31, 2012, retaining the $30 million total availability under the line per the 2009 amendment. The revised agreement retained the $10 million sublimit for borrowings supported by guarantees from stockholders who are affiliates of two members of its board of directors (“Lenders”) and considered to be related parties. Under the revised facility the Company is required to maintain a minimum “tangible net worth” and liquidity ratio as defined in the agreement. Interest on the facility accrued at the rate of prime plus 0.5% subject to a floor of 6% for the amount under guarantee and prime plus 1.75% subject to a floor of 7% for the remaining amounts.

In September 2011, the Company amended its agreement with its primary lender. The amendment reduced the availability amount of all credit extensions, other than the term loan, from $30 million to $20 million, and modified the interest rate applicable to the term loan from the lender’s prime rate plus 3.5% to the lender’s prime rate plus 5.5%.

On November 30, 2011, the Company entered into a Second Amended and Restated Loan and Security Agreement with its primary lender (“Amended Loan Agreement”). Under the Amended Loan Agreement, the Company agreed to revised tangible net worth and liquidity ratio covenants. Further, certain intellectual property assets of the Company were added to the collateral which secures repayment of the loan. Finally, the Amended Loan Agreement permits the Company to repay Cowen Healthcare Royalty Partners II, L.P. (“Cowen”) under the Agreement with the royalties due to the Company under the Biosense Agreement (the "Biosense Agreement"), as described below.

On March 30, 2012, the Company amended its agreement with its primary lender. The amendment extended the maturity date of the working capital line of credit from March 31, 2012 to April 30, 2012 and reduced the Company’s borrowing availability by $3,333,333. The Company also extended until April 30, 2012 the $10 million guarantee provided by the Lenders. As a result of this extension, the Company issued the Lenders warrants to purchase 75,735 shares of common stock at $6.60 per share.

On May 1, 2012, the Company and its primary lender entered into an agreement in which the lender extended the maturity of the revolving line of credit from April 30, 2012 to May 15, 2012. The Company also amended its agreement with the Lenders to extend the $10 million loan guarantee through May 15, 2012. The Company granted warrants to purchase an aggregate of 60,976 shares of Common Stock in exchange for the extension of the guarantee.

On May 10, 2012, upon closing of financing transactions for gross proceeds of $18.5 million, the Company entered into the Third Loan Modification Agreement with its primary lender. The amendment extended the revolving credit facility maturity to March 31, 2013 and revised the financial covenants. Additionally, the revolving line of credit was decreased from $20 million to $13 million. The reduction was as result of the pay down of $7 million of the guarantees provided by the Lenders.

As of June 30, 2012, the Company had $8.0 million outstanding under the revolving line of credit. Draws on the line of credit are made based on the borrowing capacity one week in arrears. As of June 30, 2012, the Company had a borrowing capacity of $8.0 million based on the Company’s collateralized assets, including amounts already drawn. As such, the Company had no remaining borrowing availability at June 30, 2012. As of June 30, 2012, the Company was in compliance with all covenants of the bank loan agreement and had no remaining availability on its Lender loan and guarantee.

Term note

Under the 2010 amendment to the loan agreement, the Company entered into a $10 million term loan maturing on December 31, 2013, with $2 million of principal due in 2011 and $4 million of principal due in each of 2012 and 2013. Interest on the term loan accrued at the rate of prime plus 3.5%. Under the September 2011 amendment of the loan agreement, the interest rate on the term loan was increased to prime plus 5.5%. Under this agreement, the Company provided its primary lender with warrants to purchase 11,111 shares of common stock. The warrants are exercisable at $36.00 per share, beginning on December 17, 2010 and expiring on December 17, 2015. The fair value of these warrants of $228,332, calculated using the Black Scholes method, will be deferred and amortized to interest expense ratably over the life of the term loan.

Cowen Debt

In November 2011, the Company entered into a loan agreement with Cowen. Under the agreement the Company borrowed from Cowen $15 million. The Company may borrow up to an additional $5 million in the aggregate based on the achievement by the Company of certain milestones related to Niobe system sales in 2012. The loan will be repaid through, and secured by, royalties payable to the Company under its Development, Alliance and Supply Agreement with Biosense Webster, Inc. The Biosense Agreement relates to the development and distribution of magnetically enabled catheters used with Stereotaxis' Niobe system in cardiac ablation procedures. Under the terms of the Agreement, Cowen will be entitled to receive 100% of all royalties due to the Company under the Biosense Agreement until the loan is repaid. The loan is a full recourse loan, matures on December 31, 2018, and bears interest at an annual rate of 16% payable quarterly with royalties received under the Biosense Agreement. If the payments received by the Company under the Biosense Agreement are insufficient to pay all amounts of interest due on the loan, then such deficiency will increase the outstanding principal amount on the loan. After the loan obligation is repaid, the royalties under the Biosense Agreement will again be paid to the Company. The loan is also secured by certain assets and intellectual property of the Company. The Agreement also contains customary affirmative and negative covenants. The use of payments due to the Company under the Biosense Agreement was approved by our primary lender under the Amended Loans Agreement described above.

On July 30, 2012, the Company gave irrevocable notice to borrow an additional $2.5 million based upon achievement of the milestone related to Niobe system sales. Refer to Note 14 for additional discussion.

Subordinated Convertible Debentures

In May 2012, the Company entered into a securities purchase agreement with certain institutional investors whereby the Company agreed to sell an aggregate of approximately $8.5 million in aggregate principal amount of unsecured, subordinated, convertible debentures, which became convertible into shares of the Company’s common stock at a conversion price of $3.361 per share (or approximately 2.5 million shares in the aggregate), on July 10, 2012, the date that the Company received shareholder approval for the transaction. The purchasers of the debentures also received six-year warrants to purchase an aggregate of approximately 2.5 million shares of the Company’s common stock at an exercise price of $3.361 per share. The debentures bear interest at 8% per year and mature on May 7, 2014. In addition, the Company has the ability to issue shares of its common stock in lieu of cash interest payments under certain circumstances, and intends to do so at such time as the Company has registered the shares for resale.

The Company recorded the subordinated convertible debentures on the balance sheet net of the debt discount of $7.5 million. The debt discount is due to warrants issued in conjunction with the debentures and the debt conversion features. The fair value of the warrants and derivative liability were $4.1 million and $3.5 million, respectively. The debt discount will be amortized over the life of the loan using the effective interest method. Refer to Note 11 for additional discussion of the fair value of the warrants and conversion features.

Biosense Webster Advance

In July 2008, the Company and Biosense Webster entered into an amendment to their existing agreements relating to the development and sale of catheters. Pursuant to the amendment, Biosense Webster agreed to pay to the Company $10.0 million as an advance on royalty amounts that were owed at the time the amendment was executed or would be owed in the future by Biosense Webster to the Company pursuant to the royalty provisions of one of the existing agreements. The Company and Biosense Webster also agreed that an aggregate of up to $8.0 million of certain agreed upon research and development expenses that were owed at the time the amendment was executed or may be owed in the future by the Company to Biosense Webster pursuant to the existing agreement would be deferred and will be due, together with any unrecouped portion of the $10.0 million royalty advance, no later than December 31, 2011. Interest on the outstanding and unrecouped amounts of the royalty advance and deferred research and development expenses accrued at an interest rate of the prime rate plus 0.75%. Outstanding royalty advances and deferred research and development expenses and accrued interest thereon were recouped by Biosense Webster by deductions from royalty amounts otherwise owed to the Company from Biosense Webster pursuant to the existing agreement. Approximately $18.0 million had been advanced by Biosense Webster to the Company pursuant to the amendment. As of December 31, 2011, these amounts plus interest accrued thereon had been repaid in full, in accordance with the agreement.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References + Details

Stockholders' Equity

6 Months Ended

Jun. 30, 2012

Stockholders' Equity [Abstract]

Stockholders' Equity

10. Stockholders’ Equity

Reverse Stock Split

On July 10, 2012, the Company filed a Certificate of Amendment to our Amended and Restated Certificate of Incorporation to implement a one-for-ten reverse split of our common stock (the “Reverse Stock Split”). The ratio for the Reverse Stock Split was determined by our Board of Directors pursuant to the approval of the stockholders at the Company’s special meeting of stockholders held on July 10, 2012, authorizing the Board to effect a reverse stock split within a range of one-for-four to one-for-ten shares of the Company’s common stock. The Reverse Stock Split was effective as of July 10, 2012, and the Company’s common stock began trading on the NASDAQ Global Market on a post-split basis on July 11, 2012.

As a result of the Reverse Stock Split, each ten shares of the Company’s issue d and outstanding common stock were automatically combined and converted into one issued and outstanding share of common stock. The Reverse Stock Split affected all issued and outstanding warrants and convertible debentures outstanding immediately prior to the effectiveness of the Reverse Stock Split. The Reverse Stock Split reduced the number of shares of the Company’s common stock currently outstanding from approximately 78 million to 7.8 million. In addition, the Amendment increased the number of authorized shares of the Company’s common stock from 100 million to 300 million. The Reverse Stock Split did not alter the par value of common stock, which remained $0.001 per share, or modify any voting rights or other terms of the Company’s common stock. Unless otherwise indicated, all information set forth herein gives effect to such Reverse Stock Split.

PIPE Transaction

In May 2012, the Company entered into a Stock and Warrant Purchase Agreement with certain institutional investors whereby it agreed to sell an aggregate of approximately 21.7 million shares of the Company's common stock (the “PIPE Common Stock”) at a price of $0.3361 per share, together with six-year warrants at a price of $0.125 per share to purchase an aggregate of approximately 21.7 million shares of common stock having an exercise price of $0.3361 per share (the “PIPE Warrants”). Each purchaser received a PIPE Warrant to purchase one share of common stock for every share of PIPE Common Stock purchased.

As described above, on July 10, 2012, the Company effected a one-for-ten Reverse Stock Split of the Company’s common stock. As a result, the PIPE Common Stock was combined and converted into an aggregate of approximately 2.17 million shares of the Company’s common stock, and the PIPE Warrants became exercisable for an aggregate of approximately 2.17 million shares with an exercise price of $3.361 per share.

Net proceeds from the sale of the securities were approximately $9.1 million, after placement agent fees and other offering expenses. The Company used the funds to repay $7 million of the revolving credit facility guaranteed by the Lenders and plans to use the balance for working capital and general corporate purposes.

Stock Award Plans

The Company has various stock plans that permit the Company to provide incentives to employees and directors of the Company in the form of equity compensation that are described in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011. At June 30, 2012, the Board of Directors had no remaining shares of the Company’s common stock to provide for current and future grants under its various equity plans. At the 2012 Annual Shareholder Meeting, the Board of Directors is seeking shareholder approval for a 2012 Stock Incentive Plan.

At June 30, 2012, the total compensation cost related to options, stock appreciation rights and non-vested stock granted to employees under the Company’s stock award plans but not yet recognized was approximately $5.3 million, net of estimated forfeitures of approximately $2.6 million. This cost will be amortized over a period of up to four years on a straight-line basis over the underlying estimated service periods and will be adjusted for subsequent changes in estimated forfeitures and anticipated vesting periods.

A summary of the option and stock appreciation rights activity for the six months ended June 30, 2012 is as follows:

	Number of Options/SARs	Range of Exercise Price	Weighted Average Exercise Price per Share

Outstanding, December 31, 2011	562,733	$10.00 - $125.50	$48.53
Granted	5,423	$6.80 - $8.10	$7.53
Exercised	-	$0.00 - $0.00	-
Forfeited	(144,487)	$6.90 - $125.50	$57.52
Outstanding, June 30, 2012	423,669	$6.80 - $116.40	$44.95

A summary of the restricted share grant activity for the six months ended June 30, 2012 is as follows:

	Number of Shares	Weighted Average Grant Date Fair Value per Share

Outstanding, December 31, 2011	52,659	$34.20
Granted	85,250	$8.00
Vested	(3,959)	$37.30
Forfeited	(21,175)	$20.90
Outstanding, June 30, 2012	112,775	$16.80

A summary of the restricted stock unit activity for the six months ended June 30, 2012 is as follows:

	Number of Restricted Shares Units	Weighted Average Grant Date Fair Value per Unit

Outstanding, December 31, 2011	98,820	$ 10.90
Granted	14,471	$ 8.50
Vested	(17,631)	$ 10.90
Forfeited	(13,554)	$ 6.90

Outstanding, June 30, 2012	82,106	$ 11.10

A summary of the restricted stock outstanding as of June 30, 2012 is as follows:

	Number of Shares

Time based restricted shares	12,125
Performance based restricted shares	100,650
Outstanding, June 30, 2012	112,775

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 4
-Section 08
-Paragraph d

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Chapter 1
-Section B
-Paragraph 7, 11A
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 3, 4, 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 21: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 22: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 23: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

+ Details

Fair Value Measurements

6 Months Ended

Jun. 30, 2012

Fair Value Measurements [Abstract]

Fair Value Measurements

11. Fair Value Measurements

Level 1: Values are based on unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

Level 2: Values are based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, or other model-based valuation techniques for which all significant assumptions are observable in the market.

Level 3: Values are generated from model-based techniques that use significant assumptions not observable in the market.

The following table sets forth the Company’s assets and liabilities measured at fair value on a recurring basis by level within the fair value hierarchy. As required by the Fair Value Measurements and Disclosures topic of the Accounting Standards Codification, assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

	Fair Value at June 30, 2012
	Total	Level 1	Level 2	Level 3
Assets at Fair Value:
Cash equivalents	$ 2,805,529	2,805,529	-	-
Derivative asset	3,951	-	-	3,951
Total Assets at Fair Value	$ 2,809,480	2,805,529	-	3,951

Liabilities at Fair Value:
Warrants issued December 29, 2008	$ 13,145	-	-	13,145
Warrants issued May 10, 2012	1,379,713	-	-	1,379,713
Derivative liability	686,246	-	-	686,246
Total Liabilities at Fair Value:	$ 2,079,104	-	-	2,079,104

Level 1

The Company’s financial assets consist of cash equivalents invested in money market funds in the amount of $2,805,529 and $55,629 at June 30, 2012 and December 31, 2011, respectively. These assets are classified as Level 1 as described above and total interest income recorded for these investments was insignificant during both the three and six months ended June 30, 2012 and the three and six months ended June 30, 2011. There were no transfers in or out of Level 1 during the three and six months ended June 30, 2012.

Level 2

The Company does not have any financial assets or liabilities classified as Level 2.

Level 3

In conjunction with its December 29, 2008 registered direct offering, the Company issued warrants to purchase 1,792,408 shares of the Company’s common stock that contained a provision that required a reduction of the exercise price if certain equity events occurred. Under the provisions of general accounting principles for derivatives and hedging activities and determining whether an instrument (or embedded feature) is indexed to an entity’s own stock, such a reset provision does not meet the exemptions for equity classification and as such, the Company accounts for these warrants as derivative instruments. The calculated fair value of the warrants is classified as a liability and is periodically remeasured with any changes in value recognized in “Other income (expense)” in the Statement of Operations. General accounting principles for determining whether an instrument (or embedded feature) is indexed to an entity’s own stock became effective for the Company as of January 1, 2009. Accordingly, the fair value of the warrants as of that date was reclassified from stockholders’ equity into current liabilities.

In accordance with general accounting principles for fair value measurement, the Company’s warrants in the amount of $13,145 were measured at fair value on a recurring basis as of June 30, 2012 and were valued using Level 3 valuation inputs. A Black-Scholes model was used to value the Company’s warrants at June 30, 2012 using the following assumptions: 1) dividend yield of 0%; 2) volatility of 77%; 3) risk-free interest rate of 0.41%; and 4) expected life of 2 years.

In the Company’s May 2012 financing transaction, the Company issued subordinated convertible debentures and warrants. The optional conversion feature of the subordinated convertible debentures is classified as a derivative liability within “Warrants and derivative liabilities” on the Company’s balance sheet. The warrants issued in conjunction with the Debentures and PIPE are also considered a liability. Due to the provisions included in the warrant agreements, the warrants do not meet the exemptions for equity classification and as such, the Company accounts for these warrants as derivative instruments. The warrants and derivative liability are periodically remeasured with any changes in value recognized in “Other income (expense)” in the Statement of Operations.

Per the terms of the Debentures agreement, the Company may require each holder to convert up to 50% of the Debentures if the common stock closes above $15.00, or 100% of the Debentures if the common stock closes above $20.00 (in each case, as adjusted for stock splits, recapitalizations and similar events) during a 20 consecutive trading day period and the resale registration statement has been declared effective by the SEC and is available for the issuance of the common stock upon conversion of the Debentures. In the event of any forced conversion by the Company, the minimum amount that the Company can force the holders to convert shall be $2.5 million of Debentures in the aggregate. This mandatory redemption clause is classified as a derivative asset within “Prepaid and other current assets” on the Company’s balance sheet. The derivative asset is periodically remeasured with any changes in value recognized in “Other income (expense)” in the Statement of Operations.

In accordance with general accounting principles for fair value measurement, the Company’s warrants, derivative liability, and derivative asset were measured at fair value on a recurring basis as of June 30, 2012 and were valued using Level 3 valuation inputs. A Monte-Carlo simulation was used to value the derivative asset and liabilities upon issuance on May 10, 2012 using the following assumptions: 1) volatility of 80%; 2) risk-free interest rate of 1.035%; and 3) a closing stock price of $0.3413. The derivative asset and liabilities were revalued as of June 30, 2012 using the following assumptions: 1) volatility of 80%; 2) risk-free interest rate of 1.035%; and 3) a closing stock price of $0.21.

The following table sets forth a summary of changes in the fair value of the Company’s Level 3 financial asset and liabilities for the six months ended June 30, 2012:

	Derivative Asset	Total Assets	Warrants issued December 29, 2008	Warrants issued May 10, 2012	Derivative Liability	Total Liabilities
Balance at beginning of period⁽¹⁾	$ 18,508	$ 18,508	$ 125,415	$ 7,573,466	$ 3,476,134	$ 11,175,015
Settlements	-	-	-	-	-	-
Revaluation	(14,557)	(14,557)	(112,270)	(6,193,753)	(2,789,888)	(9,095,911)
Balance at end of period	$ 3,951	$ 3,951	$ 13,145	$ 1,379,713	$ 686,246	$ 2,079,104

⁽¹⁾The beginning of the period is December 31, 2011 for warrants issued December 29, 2008. The beginning of the period for the derivative asset, warrants issued May 10, 2012, and derivative liability is May 10, 2012.

The Company currently does not have derivative instruments to manage its exposure to currency fluctuations or other business risks. The Company evaluates all of its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. All derivative financial instruments are recognized in the balance sheet at fair value.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44A, 44B
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15C, 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15A
-Subparagraph a-d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15B
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 3, 10, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32, 33, 34
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 17-22, 27, 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19207-110258

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13537-108611

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13433-108611

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13504-108611

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19296-110258

+ Details

Product Warranty Provisions

6 Months Ended

Jun. 30, 2012

Product Warranty Provisions [Abstract]

Product Warranty Provisions

12. Product Warranty Provisions

The Company’s standard policy is to warrant all Niobe and Odyssey systems against defects in material or workmanship for one year following installation. The Company’s estimate of costs to service the warranty obligations is based on historical experience and current product performance trends. A regular review of warranty obligations is performed to determine the adequacy of the reserve and adjustments are made to the estimated warranty liability as appropriate.

Accrued warranty, which is included in other accrued liabilities, consists of the following:


	June 30,
	2012

Warranty accrual, December 31, 2011	$691,832
Warranty expense incurred	256,866
Payments made	(355,275)
Warranty accrual, June 30, 2012	$593,423

Commitments And Contingencies	6 Months Ended
Commitments And Contingencies	Jun. 30, 2012
Commitments And Contingencies [Abstract]
Commitments And Contingencies	*13. Commitments and Contingencies* The Company at times becomes a party to claims in the ordinary course of business. Management believes that the ultimate resolution of pending or threatened proceedings will not have a material effect on the financial position, results of operations or liquidity of the Company. In 2011, the Company entered into a letter of credit to support a commitment in the amount of less than $0 .1 million. This letter of credit is valid through 2015.

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 14
-Paragraph 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 9, 10, 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

+ Details

Subsequent Events	6 Months Ended
Subsequent Events	Jun. 30, 2012
Subsequent Events [Abstract]
Subsequent Events	*14. Subsequent Events* On July 30, 2012, the Company gave irrevocable notice to borrow an additional $2.5 million on August 14, 2012 based on the achievement of certain milestones related to Niobe system sales in 2012 in accordance with the Cowen loan agreement.

Summary Of Significant Accounting Policies (Policy)

6 Months Ended

Jun. 30, 2012

Summary Of Significant Accounting Policies [Abstract]

Basis Of Presentation

Basis of Presentation

Revenue And Costs Of Revenue

Revenue and Costs of Revenue

Net Earnings (Loss) Per Common Share

Net Earnings (Loss) per Common Share

The following table sets forth the computation of basic and diluted EPS:

	Three months ended June 30,		Six months ended June 30,
	2012	2011	2012	2011
Numerator:
Numerator for basic EPS	$ 2,806,427	$ (9,694,685)	$ (3,006,485)	$ (19,244,618)

Effect of dilutive securities:
Convertible debentures	203,830	-	-	-

Numerator for diluted EPS	$ 3,010,257	$ (9,694,685)	$ (3,006,485)	$ (19,244,618)

Denominator:
Denominator for basic EPS - weighted average shares	6,741,578	5,478,087	6,120,447	5,475,044

Effect of dilutive securities:
Convertible debentures	2,521,571	-	-	-

Denominator for diluted EPS	9,263,149	5,478,087	6,120,447	5,475,044

Basic EPS	$ 0.42	$ (1.77)	$ (0.49)	$ (3.51)
Diluted EPS	$ 0.32	$ (1.77)	$ (0.49)	$ (3.51)

Fair Value Measurements

Fair Value Measurements

The following methods and assumptions were used by the Company in estimating its fair value disclosures for other financial instruments as of June 30, 2012 and December 31, 2011.

Long and short-term debt fair value estimates are based on estimated borrowing rates to discount the cash flows to their present value. See Note 9 for disclosure of the fair value of debt.

Share-Based Compensation

Share-Based Compensation

Reclassifications

Reclassifications

- Definition

Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.

+ References + Details

- Definition

Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.

+ References + Details

Summary Of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2012

Summary Of Significant Accounting Policies [Abstract]

Computation Of Basic And Diluted EPS

	Three months ended June 30,		Six months ended June 30,
	2012	2011	2012	2011
Numerator:
Numerator for basic EPS	$ 2,806,427	$ (9,694,685)	$ (3,006,485)	$ (19,244,618)

Effect of dilutive securities:
Convertible debentures	203,830	-	-	-

Numerator for diluted EPS	$ 3,010,257	$ (9,694,685)	$ (3,006,485)	$ (19,244,618)

Denominator:
Denominator for basic EPS - weighted average shares	6,741,578	5,478,087	6,120,447	5,475,044

Effect of dilutive securities:
Convertible debentures	2,521,571	-	-	-

Denominator for diluted EPS	9,263,149	5,478,087	6,120,447	5,475,044

Basic EPS	$ 0.42	$ (1.77)	$ (0.49)	$ (3.51)
Diluted EPS	$ 0.32	$ (1.77)	$ (0.49)	$ (3.51)

Inventory (Tables)

6 Months Ended

Jun. 30, 2012

Inventory [Abstract]

Schedule Of Inventory


	June 30,	December 31,
	2012	2011

Raw materials	$3,532,122	$2,264,603
Work in process	354,344	131,980
Finished goods	3,723,835	3,790,625
Reserve for obsolescence	(231,706)	(151,157)
Total inventory	$7,378,595	$6,036,051

Prepaid Expenses And Other Current Assets (Tables)

6 Months Ended

Jun. 30, 2012

Prepaid Expenses And Other Current Assets [Abstract]

Schedule Of Prepaid Expenses And Other Current Assets


	June 30,	December 31,
	2012	2011

Prepaid expenses	$390,292	$460,297
Deferred cost of revenue	389,860	289,312
Derivative asset	3,951	-
Other assets	3,074,721	2,331,875
Total prepaid expenses and other current assets	$3,858,824	$3,081,484

Property And Equipment (Tables)

6 Months Ended

Jun. 30, 2012

Property And Equipment [Abstract]

Schedule Of Property And Equipment


	June 30,	December 31,
	2012	2011

Equipment	$8,946,967	$8,977,623
Equipment held for lease	547,416	547,416
Leasehold improvements	2,473,880	2,473,880
	11,968,263	11,998,919
Less: Accumulated depreciation	(9,204,540)	(8,675,063)
Net property and equipment	$2,763,723	$3,323,856

Accrued Liabilities (Tables)

6 Months Ended

Jun. 30, 2012

Accrued Liabilities [Abstract]

Schedule Of Accrued Liabilities


	June 30,	December 31,
	2012	2011

Accrued salaries, bonus, and benefits	$2,966,208	$3,229,382
Accrued research and development	19,547	27,044
Accrued legal and other professional fees	58,762	25,000
Other	2,903,185	2,421,740
Total accrued liabilities	$5,947,702	$5,703,166

Deferred Revenue (Tables)

6 Months Ended

Jun. 30, 2012

Deferred Revenue [Abstract]

Schedule Of Deferred Revenue


	June 30,	December 31,
	2012	2011

Product shipped, revenue deferred	$1,595,106	$2,001,160
Customer deposits	447,700	1,156,900
Deferred service and license fees	6,259,427	5,696,959
	8,302,233	8,855,019
Less: Long-term deferred revenue	(766,860)	(634,713)
Total current deferred revenue	$7,535,373	$8,220,306

Long-Term Debt And Credit Facilities (Tables)

6 Months Ended

Jun. 30, 2012

Long-Term Debt And Credit Facilities [Abstract]

Schedule Of Long-Term Debt Outstanding

	June 30, 2012		December 31, 2011
	Carrying	Estimated	Carrying	Estimated
	Amount	Fair Value	Amount	Fair Value

Revolving line of credit, due March 2013	$ 8,000,000	$ 8,119,966	$ 15,290,510	$ 15,371,063
Term note, due December 2013	6,000,000	6,000,000	8,000,000	8,000,000
Cowen debt	14,075,189	14,075,189	15,173,342	15,173,342
Subordinated convertible debentures	1,053,551	1,053,551	-	-
Total debt	29,128,740	29,248,706	38,463,852	38,544,405
Less current maturities	(13,891,182)	(14,011,148)	(21,173,321)	(21,253,874)
Total long term debt	$ 15,237,558	$ 15,237,558	$ 17,290,531	$ 17,290,531

Stockholder's Equity (Tables)

6 Months Ended

Jun. 30, 2012

Stockholders' Equity [Abstract]

Summary Of The Option And Stock Appreciation Rights Activity

	Number of Options/SARs	Range of Exercise Price	Weighted Average Exercise Price per Share

Outstanding, December 31, 2011	562,733	$10.00 - $125.50	$48.53
Granted	5,423	$6.80 - $8.10	$7.53
Exercised	-	$0.00 - $0.00	-
Forfeited	(144,487)	$6.90 - $125.50	$57.52
Outstanding, June 30, 2012	423,669	$6.80 - $116.40	$44.95

Summary Of The Restricted Share Grant Activity

	Number of Shares	Weighted Average Grant Date Fair Value per Share

Outstanding, December 31, 2011	52,659	$34.20
Granted	85,250	$8.00
Vested	(3,959)	$37.30
Forfeited	(21,175)	$20.90
Outstanding, June 30, 2012	112,775	$16.80

Summary Of The Restricted Stock Unit Activity

	Number of Restricted Shares Units	Weighted Average Grant Date Fair Value per Unit

Outstanding, December 31, 2011	98,820	$ 10.90
Granted	14,471	$ 8.50
Vested	(17,631)	$ 10.90
Forfeited	(13,554)	$ 6.90

Outstanding, June 30, 2012	82,106	$ 11.10

Summary Of The Restricted Stock Outstanding

	Number of Shares

Time based restricted shares	12,125
Performance based restricted shares	100,650
Outstanding, June 30, 2012	112,775

Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2012

Fair Value Measurements [Abstract]

Assets And Liabilities Measure At Fair Value On A Recurring Basis By Level

	Fair Value at June 30, 2012
	Total	Level 1	Level 2	Level 3
Assets at Fair Value:
Cash equivalents	$ 2,805,529	2,805,529	-	-
Derivative asset	3,951	-	-	3,951
Total Assets at Fair Value	$ 2,809,480	2,805,529	-	3,951

Liabilities at Fair Value:
Warrants issued December 29, 2008	$ 13,145	-	-	13,145
Warrants issued May 10, 2012	1,379,713	-	-	1,379,713
Derivative liability	686,246	-	-	686,246
Total Liabilities at Fair Value:	$ 2,079,104	-	-	2,079,104

Summary Of Changes In The Fair Value Of The Company's Level 3 Financial Asset And Liabilities

	Derivative Asset	Total Assets	Warrants issued December 29, 2008	Warrants issued May 10, 2012	Derivative Liability	Total Liabilities
Balance at beginning of period⁽¹⁾	$ 18,508	$ 18,508	$ 125,415	$ 7,573,466	$ 3,476,134	$ 11,175,015
Settlements	-	-	-	-	-	-
Revaluation	(14,557)	(14,557)	(112,270)	(6,193,753)	(2,789,888)	(9,095,911)
Balance at end of period	$ 3,951	$ 3,951	$ 13,145	$ 1,379,713	$ 686,246	$ 2,079,104

⁽¹⁾The beginning of the period is December 31, 2011 for warrants issued December 29, 2008. The beginning of the period for the derivative asset, warrants issued May 10, 2012, and derivative liability is May 10, 2012.

- Definition

Tabular disclosure of the fair value measurement of assets and liabilities which includes [financial] instruments measured at fair value that are classified in stockholders' equity. Such assets and liabilities may be measured on a recurring or nonrecurring basis. The disclosures which may be required or desired include: (1) for assets and liabilities measured on a recurring basis, disclosure may include: (a) the fair value measurements at the reporting date; (b) the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3); (c) for fair value measurements using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (i) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (ii) purchases, sales, issuances, and settlements (net); (iii) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs); (d) the amount of the total gains or losses for the period in subparagraph (c) (i) above included in earnings (or changes in net assets) that are attributable to the change in unrealized gains or losses relating to those assets and liabilities still held at the reporting date and a description of where those unrealized gains or losses are reported in the statement of income (or activities); (e) the valuation technique(s) used to measure fair value and a discussion of changes in valuation techniques, if any, during the period and (2) for assets and liabilities that are measured at fair value on a nonrecurring basis (for example, impaired assets) disclosure may include, in addition to (a) above: (a) the reasons for the fair value measurements recorded; (b) the same as (b) above; (c) for fair value measurements using significant unobservable inputs (Level 3), a description of the inputs and the information used to develop the inputs; and (d) the valuation technique(s) used to measure fair value and a discussion of changes, if any, in the valuation technique(s) used to measure similar assets and/or liabilities in prior periods. Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 33
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 6
-Footnote 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19207-110258

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19190-110258

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19279-110258

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19296-110258

+ Details

Product Warranty Provisions (Tables)

6 Months Ended

Jun. 30, 2012

Product Warranty Provisions [Abstract]

Schedule Of Accrued Warranty


	June 30,
	2012

Warranty accrual, December 31, 2011	$691,832
Warranty expense incurred	256,866
Payments made	(355,275)
Warranty accrual, June 30, 2012	$593,423

Description Of Business (Details)	1 Months Ended	6 Months Ended
Description Of Business (Details)	May 31, 2012 USD ($)	Jun. 30, 2012 USD ($)	Dec. 31, 2011 USD ($)
Description Of Business [Line Items]
Cumulative losses incurred from inception		$ (378,413,931)	$ (375,407,446)
Installations to upgrade		47
Proceeds from financing agreement	$ 18,500,000
Maximum [Member]
Description Of Business [Line Items]
Annual plan to rebalance and reduce operating expenses, percentage		20.00%
Minimum [Member]
Description Of Business [Line Items]
Annual plan to rebalance and reduce operating expenses, percentage		15.00%

Summary Of Significant Accounting Policies (Narrative) (Details)		3 Months Ended	6 Months Ended
	Jul. 10, 2012	Jun. 30, 2012 USD ($) $ / shares shares	Jun. 30, 2012 USD ($) $ / shares shares	Dec. 31, 2011 $ / shares shares
Summary Of Significant Accounting Policies [Line Items]
Reverse stock split	0.1
Proceeds from sale of unsecured, subordinated, convertible debentures \| $			$ 8,500,000
Conversion price of convertible debt \| $ / shares		$ 3.361	$ 3.361
Number of shares converted		2,521,571
Convertible debentures \| $		$ 203,830
Stock options and stock appreciation rights		423,669	423,669	562,733
Restricted share awards		112,775	112,775
Restricted stock units		82,106	82,106
Warrants		6,099,476	6,099,476
Weighted average exercise price \| $ / shares		$ 44.95	$ 44.95	$ 48.53
Weighted average exercise price of warrants or rights \| $ / shares		$ 9.98	$ 9.98
Restricted Stock [Member]
Summary Of Significant Accounting Policies [Line Items]
Weighted average unearned restricted shares outstanding		111,226	98,098

Summary Of Significant Accounting Policies (Computation Of Basic And Diluted EPS) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
Summary Of Significant Accounting Policies [Abstract]
Numerator for basic EPS	$ 2,806,427	$ (9,694,685)	$ (3,006,485)	$ (19,244,618)
Convertible debentures	203,830
Numerator for diluted EPS	$ 3,010,257	$ (9,694,685)	$ (3,006,485)	$ (19,244,618)
Denominator for basic EPS - weighted average shares	6,741,578	5,478,087	6,120,447	5,475,044
Convertible debentures	2,521,571
Denominator for diluted EPS	9,263,149	5,478,087	6,120,447	5,475,044
Basic EPS	$ 0.42	$ (1.77)	$ (0.49)	$ (3.51)
Diluted EPS	$ 0.32	$ (1.77)	$ (0.49)	$ (3.51)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 36, 37, 38
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 5
-Section 03
-Paragraph 20

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 7
-Paragraph 18

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 21
-Article 9

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.21)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6920599&loc=d3e1252-109256

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=6945512&loc=d3e4984-109258

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.23)
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 07-4
-Paragraph 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 87-21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 10, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28, 29, 30
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 5
-Section 03
-Paragraph 19

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e565-108580

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A7
-Appendix A

+ Details

- Definition

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

+ References + Details

- Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 171
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 40
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6920599&loc=d3e1448-109256

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Weighted-Average Number of Common Shares Outstanding
-URI http://asc.fasb.org/extlink&oid=6528421

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 07-4
-Paragraph 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Inventory (Schedule Of Inventory) (Details) - USD ($)	Jun. 30, 2012	Dec. 31, 2011
Inventory [Abstract]
Raw materials	$ 3,532,122	$ 2,264,603
Work in process	354,344	131,980
Finished goods	3,723,835	3,790,625
Reserve for obsolescence	(231,706)	(151,157)
Total inventory	$ 7,378,595	$ 6,036,051

- Definition

The amount of the valuation account as of the balance sheet date which reduces the carrying amount of inventory to net realizable value; takes into consideration such factors as market value, excessive quantities based on expected sales, technological obsolescence, and shrinkage. May also provide for estimated product returns or price concessions pertaining to product cost.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 6
-Subparagraph a
-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Chapter 3
-Section A
-Paragraph 9
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Chapter 4
-Paragraph 14
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Chapter 4
-Paragraph 8, 9, 14
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 09
-Article 12

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 5.BB)
-URI http://asc.fasb.org/extlink&oid=6386940&loc=d3e100047-122729

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SX 210.12-09)
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e24092-122690

+ Details

Prepaid Expenses And Other Current Assets (Schedule Of Prepaid Expenses And Other Current Assets) (Details) - USD ($)	Jun. 30, 2012	Dec. 31, 2011
Prepaid Expenses And Other Current Assets [Abstract]
Prepaid expenses	$ 390,292	$ 460,297
Deferred cost of revenue	389,860	289,312
Derivative asset	3,951
Other assets	3,074,721	2,331,875
Total prepaid expenses and other current assets	$ 3,858,824	$ 3,081,484

Property And Equipment (Schedule Of Property And Equipment) (Details) - USD ($)	Jun. 30, 2012	Dec. 31, 2011
Property And Equipment [Abstract]
Equipment	$ 8,946,967	$ 8,977,623
Equipment held for lease	547,416	547,416
Leasehold improvements	2,473,880	2,473,880
Gross property and equipment	11,968,263	11,998,919
Less: Accumulated depreciation	(9,204,540)	(8,675,063)
Net property and equipment	$ 2,763,723	$ 3,323,856

- Definition

The cumulative amount of depreciation, depletion and amortization (related to property, plant and equipment, but not including land) that has been recognized in the income statement.

+ References + Details

Intangible Assets (Details) - USD ($) $ in Millions	Jun. 04, 2010	Jun. 30, 2012
Intangible Assets [Abstract]
Total shares to exchange for intellectual property on agreement	450,000
Shares issued upon execution of agreement	200,000
Aggregate shares to be issued in annual installments on the first three anniversaries of the agreement	250,000
Total intangible assets, including those subject to execution of agreement		$ 3.7
Accumulated amortization		$ 1.0

Accrued Liabilities (Schedule Of Accrued Liabilities) (Details) - USD ($)	Jun. 30, 2012	Dec. 31, 2011
Accrued Liabilities [Abstract]
Accrued salaries, bonus, and benefits	$ 2,966,208	$ 3,229,382
Accrued research and development	19,547	27,044
Accrued legal and other professional fees	58,762	25,000
Other	2,903,185	2,421,740
Total accrued liabilities	$ 5,947,702	$ 5,703,166

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References + Details

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References + Details

Deferred Revenue (Schedule Of Deferred Revenue) (Details) - USD ($)	Jun. 30, 2012	Dec. 31, 2011
Deferred Revenue Arrangement [Line Items]
Deferred revenue	$ 8,302,233	$ 8,855,019
Less: Long-term deferred revenue	(766,860)	(634,713)
Total current deferred revenue	7,535,373	8,220,306
Product Shipped, Revenue Deferred [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue	1,595,106	2,001,160
Customer Deposits [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue	447,700	1,156,900
Deferred Service And License Fees [Member]
Deferred Revenue Arrangement [Line Items]
Deferred revenue	$ 6,259,427	$ 5,696,959

- Definition

The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References + Details

Long-Term Debt And Credit Facilities (Narrative) (Details)		1 Months Ended				3 Months Ended	6 Months Ended
	May 10, 2012 USD ($)	May 31, 2012 USD ($) $ / shares shares	Mar. 30, 2012 USD ($) $ / shares shares	Nov. 30, 2011 USD ($)	Dec. 31, 2010 USD ($)	Jun. 30, 2012 USD ($) $ / shares shares	Jun. 30, 2012 USD ($) $ / shares shares	May 01, 2012 USD ($) shares	Sep. 30, 2011 USD ($)	Jul. 31, 2008 USD ($)
Debt Instrument [Line Items]
Number of warrants issued \| shares						6,099,476	6,099,476
Fair value of warrants issued						$ 13,145	$ 13,145
Paydown of the guarantees							7,000,000
Proceeds from Convertible Debt							$ 8,500,000
Conversion price per share \| $ / shares						$ 3.361	$ 3.361
Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Line of credit facility, amount outstanding						$ 8,000,000	$ 8,000,000
Line of credit facility, remaining borrowing capacity						$ 8,000,000
Term Note [Member]
Debt Instrument [Line Items]
Number of warrants issued \| shares						11,111	11,111
Exercise price of warrants \| $ / shares						36.00	36.00
Fair value of warrants issued						$ 228,332	$ 228,332
Term loan agreement, face value						10,000,000	10,000,000
Cowen Debt [Member]
Debt Instrument [Line Items]
Amount borrowed				$ 15,000,000
Additional amount which may be borrowed				$ 5,000,000
Percentage of royalties entitled to				100.00%
Annual interest rate				16.00%
Additional amount borrowed							2,500,000
Subordinated Convertible Debentures [Member]
Debt Instrument [Line Items]
Number of warrants issued \| shares		2,500,000
Exercise price of warrants \| $ / shares		3.361
Annual interest rate		8.00%
Proceeds from Convertible Debt		$ 8,500,000
Conversion price per share \| $ / shares		$ 3.361
Number of convertible shares		2,500,000
Debt discount						7,500,000	7,500,000
Fair value of warrants						4,100,000	4,100,000
Fair value of derivative liability						3,500,000	3,500,000
Biosense Webster Advance [Member]
Debt Instrument [Line Items]
Advance on royalty amounts										$ 18,000,000
2009 Amendment [Member] \| Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity					$ 30,000,000
Accrued interest on facility, floor					7.00%
Guarantees From Stockholders [Member] \| Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity					$ 10,000,000
Accrued interest on facility, floor					6.00%
March 30, 2012 Amendment [Member] \| Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity			$ 10,000,000
Decrease in maximum borrowing capacity			$ 3,333,333
Number of warrants issued \| shares			75,735
Exercise price of warrants \| $ / shares			6.60
May 1, 2012 Agreement [Member] \| Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity								$ 10,000,000
Number of warrants issued \| shares								60,976
May 10, 2012 Amendment [Member] \| Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 20,000,000
Current borrowing capacity	13,000,000
Paydown of the guarantees	7,000,000
Net proceeds from issuance of long-term debt	$ 18,500,000
September 2011 Amendment [Member] \| Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity									$ 20,000,000
Principal Due 2013 [Member] \| Term Note [Member]
Debt Instrument [Line Items]
Term loan principal amount due						4,000,000	4,000,000
Principal Due 2012 [Member] \| Term Note [Member]
Debt Instrument [Line Items]
Term loan principal amount due						4,000,000	4,000,000
Principal Due 2011 [Member] \| Term Note [Member]
Debt Instrument [Line Items]
Term loan principal amount due						$ 2,000,000	$ 2,000,000
Research And Development Expenses [Member] \| Biosense Webster Advance [Member]
Debt Instrument [Line Items]
Advance on royalty amounts										8,000,000
Royalty Amounts [Member] \| Biosense Webster Advance [Member]
Debt Instrument [Line Items]
Advance on royalty amounts										$ 10,000,000
Prime Rate Plus [Member] \| Biosense Webster Advance [Member]
Debt Instrument [Line Items]
Variable rate on interest										0.75%
Prime Rate Plus [Member] \| 2009 Amendment [Member] \| Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Variable rate on interest					1.75%
Prime Rate Plus [Member] \| Guarantees From Stockholders [Member] \| Revolving Line Of Credit [Member]
Debt Instrument [Line Items]
Variable rate on interest					0.50%
Prime Rate Plus [Member] \| September 2011 Amendment [Member] \| Term Note [Member]
Debt Instrument [Line Items]
Variable rate on interest						5.50%	5.50%
Prime Rate Plus [Member] \| 2010 Amendment To Loan Agreement [Member] \| Term Note [Member]
Debt Instrument [Line Items]
Variable rate on interest						3.50%	3.50%

Long-Term Debt And Credit Facilities (Schedule Of Long-Term Debt Outstanding) (Details) - USD ($)	Jun. 30, 2012	Dec. 31, 2011
Debt Instrument [Line Items]
Total debt, Carrying Amount	$ 29,128,740	$ 38,463,852
Total debt, Estimated Fair Value	29,248,706	38,544,405
Less current maturities, Carrying Amount	(13,891,182)	(21,173,321)
Less current maturities, Estimated Fair Value	(14,011,148)	(21,253,874)
Total long term debt, Carrying Amount	15,237,558	17,290,531
Total long term debt, Estimated Fair Value	15,237,558	17,290,531
Revolving Credit Agreement, Due March 2013 [Member]
Debt Instrument [Line Items]
Total debt, Carrying Amount	8,000,000	15,290,510
Total debt, Estimated Fair Value	8,119,966	15,371,063
Term Note, Due December 2013 [Member]
Debt Instrument [Line Items]
Total debt, Carrying Amount	6,000,000	8,000,000
Total debt, Estimated Fair Value	6,000,000	8,000,000
Cowen Debt [Member]
Debt Instrument [Line Items]
Total debt, Carrying Amount	14,075,189	15,173,342
Total debt, Estimated Fair Value	14,075,189	$ 15,173,342
Subordinated Convertible Debentures [Member]
Debt Instrument [Line Items]
Total debt, Carrying Amount	1,053,551
Total debt, Estimated Fair Value	$ 1,053,551

Stockholders' Equity (Narrative) (Details) $ in Millions			1 Months Ended	6 Months Ended
Stockholders' Equity (Narrative) (Details) $ in Millions	Jul. 10, 2012 $ / shares	Jul. 10, 2012 $ / shares shares	May 31, 2012 $ / shares shares	Jun. 30, 2012 USD ($) $ / shares shares	Dec. 31, 2011 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Reverse stock split	0.1
Common stock outstanding				7,812,206	5,543,157
Common stock authorized				100,000,000	100,000,000
Common stock authorized due to Amendment				300,000,000
Common stock par value \| $ / shares				$ 0.001	$ 0.001
Net proceeds from sale of securities \| $				$ 9.1
Paydown of the guarantees \| $				7.0
Total compensation cost not yet recognized related to options, stock appreciation rights and non-vested stock granted to employees \| $				5.3
Estimated forfeitures \| $				$ 2.6
Total compensation cost not yet recognized related to options, stock appreciation rights and non-vested stock granted to employees, period of amortization, in years				4
Pre-Stock Split [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock outstanding				78,000,000
Shares sold in private placement			21,700,000
Share price of shares sold in private placement \| $ / shares			0.3361
Warrants sold in private placement			21,700,000
Share price of warants sold in private placement \| $ / shares			$ 0.125
Exercise price of warrants \| $ / shares			0.3361
Post-Stock Split [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock outstanding				7,800,000
Shares sold in private placement		2,170,000
Warrants sold in private placement		2,170,000
Exercise price of warrants \| $ / shares	3.361	3.361

Stockholders' Equity (Summary Of The Option And Stock Appreciation Rights Activity) (Details) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2012	Dec. 31, 2011
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options/SARs, Outstanding, December 31, 2011	562,733
Number of Options/SARs, Granted	5,423
Number of Options/SARs, Exercised
Number of Options/SARs, Forfeited	(144,487)
Number of Options/SARs, Outstanding, June 30, 2012	423,669	562,733
Weighted Average Exercise Price per Share, Outstanding, December 31, 2011	$ 48.53
Weighted Average Exercise Price per Share, Granted	7.53
Weighted Average Exercise Price per Share, Exercised
Weighted Average Exercise Price per Share, Forfeited	57.52
Weighted Average Exercise Price per Share, Outstanding, June 30, 2012	44.95	$ 48.53
$10.00 - $125.50 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, Lower limit		10.00
Range of Exercise Price, Upper limit		$ 125.50
$6.80 - $8.10 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, Lower limit	6.80
Range of Exercise Price, Upper limit	8.10
$0.00 - $0.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, Lower limit	0.00
Range of Exercise Price, Upper limit	0.00
$6.90 - $125.50 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, Lower limit	6.90
Range of Exercise Price, Upper limit	125.50
$6.80 - $116.40 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, Lower limit	6.80
Range of Exercise Price, Upper limit	$ 116.40

Stockholders' Equity (Summary Of The Restricted Share Grant Activity) (Details) - Restricted Stock [Member]	6 Months Ended
	Jun. 30, 2012 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding, December 31, 2011 \| shares	52,659
Number of Shares, Granted \| shares	85,250
Number of Shares, Vested \| shares	(3,959)
Number of Shares, Forfeited \| shares	(21,175)
Number of Shares, Outstanding, June 30, 2012 \| shares	112,775
Weighted Average Grant Date Fair Value per Share/Unit, Outstanding, December 31, 2011 \| $ / shares	$ 34.20
Weighted Average Grant Date Fair Value per Share/Unit, Granted \| $ / shares	8.00
Weighted Average Grant Date Fair Value per Share/Unit, Vested \| $ / shares	37.30
Weighted Average Grant Date Fair Value per Share/Unit, Forfeited \| $ / shares	20.90
Weighted Average Grant Date Fair Value per Share/Unit, Outstanding, June 30, 2012 \| $ / shares	$ 16.80

Stockholders' Equity (Summary Of The Restricted Stock Unit Activity) (Details) - Restricted Stock Units [Member]	6 Months Ended
	Jun. 30, 2012 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding, December 31, 2011 \| shares	98,820
Number of Shares, Granted \| shares	14,471
Number of Shares, Vested \| shares	(17,631)
Number of Shares, Forfeited \| shares	(13,554)
Number of Shares, Outstanding, June 30, 2012 \| shares	82,106
Weighted Average Grant Date Fair Value per Share/Unit, Outstanding, December 31, 2011 \| $ / shares	$ 10.90
Weighted Average Grant Date Fair Value per Share/Unit, Granted \| $ / shares	8.50
Weighted Average Grant Date Fair Value per Share/Unit, Vested \| $ / shares	10.90
Weighted Average Grant Date Fair Value per Share/Unit, Forfeited \| $ / shares	6.90
Weighted Average Grant Date Fair Value per Share/Unit, Outstanding, June 30, 2012 \| $ / shares	$ 11.10

Stockholders' Equity (Summary Of The Restricted Stock Outstanding) (Details) - Restricted Stock [Member] - shares	Jun. 30, 2012	Dec. 31, 2011
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock outstanding	112,775	52,659
Time Based Restricted Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock outstanding	12,125
Performance Based Restricted Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock outstanding	100,650

Fair Value Measurements (Narrative) (Details)		6 Months Ended
Fair Value Measurements (Narrative) (Details)	May 10, 2012 $ / shares	Jun. 30, 2012 USD ($) $ / shares shares	Dec. 31, 2011 USD ($)
Fair Value Measurements [Line Items]
Cash equivalents invested in money market funds \| $		$ 2,805,529	$ 55,629
Issued warrants to purchase shares of common stock \| shares		6,099,476
Fair value of warrants issued \| $		$ 13,145
Mandatory conversion minimum per Debentures agreement \| $		$ 2,500,000
Common Stock Closes Above $15.00 [Member]
Fair Value Measurements [Line Items]
Mandatory conversion percentage per Debentures agreement		50.00%
Share price which determines conversion per Debentures agreement \| $ / shares		15.00
Common Stock Closes Above $20.00 [Member]
Fair Value Measurements [Line Items]
Mandatory conversion percentage per Debentures agreement		100.00%
Share price which determines conversion per Debentures agreement \| $ / shares		20.00
Number of consecutive trading days required at stock price		20 days
Black-Scholes Model Used to Value Warrants [Member]
Fair Value Measurements [Line Items]
Dividend yield		0.00%
Volatility rate		77.00%
Risk-free interest rate		0.41%
Expected life		2 years
Monte-Carlo Simulation Used To Value Derivative Assets And Liabilities [Member]
Fair Value Measurements [Line Items]
Volatility rate	80.00%	80.00%
Risk-free interest rate	1.035%	1.035%
Closing stock price \| $ / shares	$ 0.3413	$ 0.21
Fair Value, Inputs, Level 3 [Member]
Fair Value Measurements [Line Items]
Issued warrants to purchase shares of common stock \| shares		1,792,408

Fair Value Measurements (Assets And Liabilities Measure At Fair Value On A Recurring Basis By Level) (Details) - USD ($)	Jun. 30, 2012	Dec. 31, 2011
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 2,805,529	$ 55,629
Derivative asset	3,951
Total Assets at Fair Value	2,809,480
Fair value of warrants issued	13,145
Derivative liability	686,246
Total Liabilities at Fair Value	2,079,104
Warrants Issued December 29, 2008 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants issued	13,145
Warrants Issued May 10, 2012 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants issued	1,379,713
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	2,805,529
Total Assets at Fair Value	2,805,529
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents
Derivative asset
Total Assets at Fair Value
Derivative liability
Total Liabilities at Fair Value
Fair Value, Inputs, Level 2 [Member] \| Warrants Issued December 29, 2008 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants issued
Fair Value, Inputs, Level 2 [Member] \| Warrants Issued May 10, 2012 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants issued
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative asset	3,951
Total Assets at Fair Value	3,951
Derivative liability	686,246
Total Liabilities at Fair Value	2,079,104
Fair Value, Inputs, Level 3 [Member] \| Warrants Issued December 29, 2008 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants issued	13,145
Fair Value, Inputs, Level 3 [Member] \| Warrants Issued May 10, 2012 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of warrants issued	$ 1,379,713

Fair Value Measurements (Summary Of Changes In The Fair Value Of The Company's Level 3 Financial Asset And Liabilities) (Details) - USD ($)

2 Months Ended

6 Months Ended

Jun. 30, 2012

Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Assets, Balance at beginning of period

^[1]

$ 18,508

Assets, Settlements

Assets, Revaluation

(14,557)

Assets, Balance at end of period

3,951

$ 3,951

Liabilities, Balance at beginning of period

^[1]

11,175,015

Liabilities, Settlements

Liabilities, Revaluations

(9,095,911)

Liabilities, Balance at end of period

2,079,104

Warrants Issued December 29, 2008 [Member]

Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Liabilities, Balance at beginning of period

^[1]

125,415

Liabilities, Settlements

Liabilities, Revaluations

(112,270)

Liabilities, Balance at end of period

13,145

Warrants Issued May 10, 2012 [Member]

Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Liabilities, Balance at beginning of period

^[1]

7,573,466

Liabilities, Revaluations

(6,193,753)

Liabilities, Balance at end of period

1,379,713

Derivative Liability [Member]

Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Liabilities, Balance at beginning of period

^[1]

3,476,134

Liabilities, Settlements

Liabilities, Revaluations

(2,789,888)

Liabilities, Balance at end of period

686,246

Derivative Asset [Member]

Fair Value, Assets And Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Assets, Balance at beginning of period

^[1]

18,508

Assets, Settlements

Assets, Revaluation

(14,557)

Assets, Balance at end of period

$ 3,951

[1]	The beginning of the period is December 31, 2011 for warrants issued December 29, 2008. The beginning of the period for the derivative asset, warrants issued May 10, 2012, and derivative liability is May 10, 2012.

Product Warranty Provisions (Schedule Of Accrued Warranty) (Details)	6 Months Ended
	Jun. 30, 2012 USD ($)
Product Warrantie Provisions [Abstract]
Warranty accrual, December 31, 2011	$ 691,832
Warranty expense incurred	256,866
Payments made	(355,275)
Warranty accrual, June 30, 2012	$ 593,423

Commitments And Contingencies (Details) $ in Millions	Dec. 31, 2011 USD ($)
Commitments And Contingencies [Abstract]
Letter of credit	$ 0.1

Subsequent Events (Details) $ in Millions	1 Months Ended
Subsequent Events (Details) $ in Millions	Jul. 30, 2012 USD ($)
Subsequent Events [Abstract]
Additional borrowings	$ 2.5